Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 6/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28916241 | 1.00 | ALOX5 (0.43) | ALOX5DRD2EPHX2MEN1KMT2A | |
| SCHEMBL28578409 | 0.88 | DRD2 (0.42) | DRD2RORCNR1H2 | |
| SCHEMBL30180740 | 0.88 | DRD2 (0.42) | DRD2RORCNR1H2 | |
| SCHEMBL28582220 | 0.84 | DRD2 (0.42) | DRD2EPHX2RORCNR1H2 | |
| SCHEMBL28582219 | 0.84 | DRD2 (0.42) | DRD2EPHX2RORCNR1H2 | |
| SCHEMBL28580754 | 0.84 | F10 (0.43) | DRD2 | |
| SCHEMBL30180480 | 0.84 | F10 (0.43) | DRD2 | |
| SCHEMBL28580755 | 0.84 | F10 (0.43) | DRD2 | |
| SCHEMBL28572167 | 0.82 | CA1 (0.45) | DRD2RORC | |
| SCHEMBL28575216 | 0.79 | CCR9 (0.49) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | ALOX5 1786/4885DRD2 4828/4885EPHX2 2249/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | ALOX5 1786/4885DRD2 4828/4885EPHX2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.